MedTrace Logo

Topical Nasal Fluticasone Propionate in the Control of Allergic Rhinitis SymptomsPerene

NCT04332978 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 566

Last updated 2020-04-08

No results posted yet for this study

Summary

Phase III Study to Demonstrate the non inferiority of PLURAIR® branded nasal topical Fluticasone Propionate (FP) in relation to the FLIXONASE® brand reference drug in the control of nasal symptoms related to perennial allergic rhinitis.

Conditions

  • Perennial Allergic Rhinitis

Interventions

DRUG

Fluticasone Propionate

Sponsors & Collaborators

  • Libbs Farmacêutica LTDA

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-04
Primary Completion
2020-04-01
Completion
2020-04-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04332978 on ClinicalTrials.gov